Traditional and New Views on MSI-H/dMMR Endometrial Cancer
Biomolecules · 26.09.2025 · 15 (10) · 1370
DOI: 10.3390/biom15101370 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 26.09.2025. Verfasst von Chuqi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Microsatellite Instability, DNA Mismatch Repair. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University, College Students' Innovation Training Program of Jining Medical University, Lin He’s Academician Workstation of New Medicine and Clinical Translation in Jining Medical University.
Abstract (Originalsprache)
MSI-H/dMMR endometrial cancer (EC) is closely linked to the mismatch repair (MMR) pathway, and its pathogenesis is associated with microsatellite instability (MSI) caused by abnormalities in the core genes of the conventional MMR system. This cancer exhibits a distinct immune microenvironment, which makes it suitable for treatment with immune checkpoint inhibitors (ICIs). This cancer type demonstrates heterogeneity, encompassing Lynch syndrome (LS)-associated EC (characterized by germline mutations), sporadic EC (attributed to MLH1 promoter hypermethylation), and Lynch-like EC (driven by somatic mutations). Research indicates that these three dMMR EC subtypes possess different immune microenvironments, which may influence the therapeutic efficacy of ICIs. However, the impact of somatic mutations in traditional MMR genes on EC has often been overlooked. Furthermore, over 50% of patients with MSI exhibit no response to ICIs, potentially due to abnormalities in nontraditional MMR genes. This review discusses the role of traditional and nontraditional MMR genes in dMMR EC and related treatment strategies, highlights key issues in the current diagnosis and treatment of dMMR EC, and aims to enhance understanding of its heterogeneity and advance precision diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lin He's Academician Workstation of New Medicine and Clinical Translation, Jining Medical University, Jining 272067, China.
- College of Clinical Medicine, Jining Medical University, Jining 272067, China.
- College of Medical Imaging and Laboratory Medicine, Jining Medical University, Jining 272067, China.
- College of Medical Laboratory, Qilu Medical University, Zibo 255300, China.
- Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China.
Förderung
- Lin He's Academician Workstation of New Medicine and Clinical Translation in Jining Medical University
- College Students' Innovation Training Program of Jining Medical University
- Lin He’s Academician Workstation of New Medicine and Clinical Translation in Jining Medical University
Zitieren
APA
Liu, C., Ping, H., Yao, M., Li, X., Li, Q., Hu, R., Xu, Y., Meng, K., Gao, F., & Meng, K. (2025). Traditional and New Views on MSI-H/dMMR Endometrial Cancer. Biomolecules, 15(10), 1370. https://doi.org/10.3390/biom15101370
Vancouver
Liu C, Ping H, Yao M, Li X, Li Q, Hu R, et al. Traditional and New Views on MSI-H/dMMR Endometrial Cancer. Biomolecules. 2025;15(10):1370. doi:10.3390/biom15101370
BibTeX
@article{Liu2025,
author = {Liu, Chuqi and Ping, Huiyu and Yao, Mengmeng and Li, Xinru and Li, Qingxin and Hu, Ruotong and Xu, Yawen and Meng, Kaidi and Gao, Fei and Meng, Kai},
title = {Traditional and New Views on MSI-H/dMMR Endometrial Cancer},
journal = {Biomolecules},
year = {2025},
volume = {15},
number = {10},
pages = {1370},
doi = {10.3390/biom15101370}
}
EUVIMED